Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis

Annals of Internal Medicine

Volumn 127, Issue 12, 1997, Pages 1080-1088

  Lee, Stephanie J ^a   Kuntz, Karen M ^b   Horowitz, Mary M ^c   McGlave, Philip B ^d   Goldman, John M ^e   Sobocinski, Kathleen A ^c   Hegland, Janet ^f   Kollman, Craig ^f   Parsons, Susan K ^a   Weinstein, Milton C ^g   Weeks, Jane C ^a   Antin, Joseph H ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NATIONAL MARROW DONOR PROGRAM   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DECISION THEORY; HUMAN; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

EID: 14444276989     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-12-199712150-00005     Document Type: Article

References (56)

1. Parker SL, Tong T, Belden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Tura S, Baccarani M, Corbelli G. Staging of chronic myeloid leukaemia. Br J Haematol. 1981;47:105-19.
3. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann Intern Med. 1995; 122:254-61.
4. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86: 906-16.
5. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-7.
6. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-5.
7. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-63.
8. Devergie A, Reiffers J, Vernant JP, Herve P, Guyotat D, Maraninchi D, et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant. 1990;5:379-86.
9. Gratwohl A, Hermans J, Baldomero H, Tichelli A, Goldman JM, Gahrton G. Indications for haemopoietic precursor cell transplants in Europe. European Group for Blood and Marrow Transplantation. Br J Haematol. 1996; 92:35-43.
10. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993;12:509-16.
11. Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Bone Marrow Transplant. 1994;13:197-201.
12. Marks DI, Cullis JO, Ward KN, Lacey S, Szydlo R, Hughes TP, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med. 1993;119:207-14.
13. Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood. 1996;88: 714-20.
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-99.
15. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985;66: 1352-7.
16. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood. 1982;60:1298-304.
17. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985; 66:1326-35.
18. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
19. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82:398-407.
20. Champlin RE, Goldman JM, Gale RP. Bone marrow transplantation in chronic myelogenous leukemia. Semin Hematol. 1988;25:74-80.
21. Karanas A, Silver RT. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968;32:445-59.
22. Spiers AS. Metamorphosis of chronic granulocytic leukaemia: diagnosis, classification, and management. Br J Haematol. 1979;41:1-7.
23. Martin PJ, Clift RA, Fisher LD, Buckner CD, Hansen JA, Appelbaum FR, et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood. 1988;72:1978-84.
24. Bortin MM, Horowitz MM, Rowlings PA, Rimm AA, Sobocinski KA, Zhang MJ, et al. 1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1993;12:97-104.
25. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543-50.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
27. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84:4064-77.
28. Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR, et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol. 1992;10: 779-89.
29. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med. 1997;126:184-92.
30. Socié G, Sobocinski K, Veum-Stone J, Horowitz MM. Long-term survival and analysis of late causes of death after allogeneic bone marrow transplantation (BMT) [Abstract]. Blood. 1996;88:643A.
31. von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. New York: Wiley; 1953.
32. Chapman GB, Elstein AS. Valuing the future: temporal discounting of health and money. Med Decis Making. 1995;15:373-86.
33. McNeil BJ, Pauker SG, Sox HC Jr, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982;306:1259-62.
34. Redelmeier DA, Heller DN. Time preference in medical decision making and cost-effectiveness analysis. Med Decis Making. 1993;13:212-7.
35. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronicphase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood. 1993;82:2975-84.
36. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-α therapy for chronic myelogenous leukemia. Am J Med. 1995;99:402-11.
37. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Haematologica. 1992;77:204-14.
38. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995;13:2401-7.
39. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996;87: 3069-81.
40. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, et al. Quantitative assessment of the relative impact of risk profile and drug therapy on survival in CML [Abstract]. Blood. 1996;88:638A.
41. Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ, et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation. 1988;45:714-8.
42. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-8.
43. Segel GB, Simon W, Lichtman MA. Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia. Blood. 1986;68:1055-64.
44. Simon W, Segel GB, Lichtman MA. Upper and lower time limits in the decision to recommend marrow transplantation for patients with chronic myelogenous leukaemia. Br J Haematol. 1988;70:31-6.
45. Bacigalupo A, Gualandi F, Van Lint MT, Sessarego M, Frassoni F, Occhini D, et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant. 1993;12:443-8.
46. Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood. 1992;80:1352-7.
47. Enright H, Daniels K, Arthur DC, Dusenbery KE, Kersey JH, Kim T, et al. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant. 1996;17:537-42.
48. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon [Editorial]. Blood. 1993;82:2273-7.
49. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-ceil dose. Blood. 1993;82: 2310-8.
50. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-6.
51. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-50.
52. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-8.
53. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-43.
54. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 1994;343:1486-8.
55. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia. Blood. 1997;89:2623-34.
56. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-9.